We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A federal appeals court has upheld a lower court’s ruling that HHS lacks the authority to require drugmakers to disclose the list prices of drugs in television advertisements. Read More
Trump administration officials announced yesterday that 300 million doses of a COVID-19 vaccine should be available by January 2021 under Operation Warp Speed although they stressed there’s no guarantee that a vaccine will be available by then. Read More
In a move to lessen India’s dependence on imports, the government is offering incentives to increase domestic manufacturing for certain drug starting materials, intermediates and active pharmaceutical ingredients (APIs). Read More
Hydroxychloroquine and chloroquine were dealt another blow as treatments for COVID-19 yesterday when the FDA revoked its Emergency Use Authorization (EUA) for the drugs — and warned that combining the antimalarials with Gilead Sciences’ remdesivir can decrease the antiviral activity of remdesivir. Read More
AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance to provide up to 400 million doses of its COVID-19 vaccine at no profit starting by the end of the year. Read More
Attorneys general from all 50 states have filed a lawsuit against dozens of generic drugmakers alleging price fixing for more than 80 topical drugs. Read More
Pfizer’s chairman and CEO Albert Bourla promised on Tuesday that the company will set an ethical price for its COVID-19 vaccine if it gains approval. Read More
AbbVie has prevailed in a lawsuit alleging that it violated antitrust laws by exploiting the patent system and making deals with companies for its blockbuster drug Humira (adalimumab). Read More
The EMA said it will continue to monitor available data on the use of medicines during the pandemic and is working with other regulators to provide advice on the safe use of medicines. Read More
Anthony Fauci, director of the NIH’s National Institute of Allergy and Infectious Diseases (NIAID), said that forcing price controls on pharmaceutical companies developing COVID-19 products will drive them away, expressing optimism that drugmakers will do the right thing on their own. Read More